Status:
COMPLETED
Hydroxychloroquine in Prevention of Preeclampsia
Lead Sponsor:
Assiut University
Conditions:
Preeclampsia
Eligibility:
FEMALE
20-40 years
Phase:
NA
Brief Summary
Pre-eclampsia complicates up to 8% of pregnancies and is a major contributor to maternal mortality and morbidity The only effective treatment is delivery, which leads to significant neonatal morbidity...
Eligibility Criteria
Inclusion
- Pregnant women in 1st 6 weeks gestation.
- History of preeclampsia in previous pregnancies.
- Women who accepted to participate
Exclusion
- Risk factors (multiple gestation, chronic hypertension, chronic renal disease).
- Known contraindication to a treatment by HCQ (retinopathy, hypersensitivity to chloroquine or HCQ, G6PD deficiency, chronic liver or kidney insufficiency, heart block, significant chronic digestive, hematologic disease epilepsy or psychotic disorders.) or disorder of lactose metabolism
- Patient already using HCQ (rheumatoid arthritis, Lupus, solar eczema). 4.impossible for follow up
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04755322
Start Date
March 1 2021
End Date
July 30 2023
Last Update
December 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abdel-rahman Mahmoud Mohammed
Asyut, Egypt